After the Global Health Golden Age: New Players, New Risks, and New Opportunities
The era of soaring global health investments is over, but a new, more complex landscape is emerging. Derek Yach, Aviva Ron, and Dorit Nitzan explore this transition in their recent perspective, The Golden Age of Global Health is Over. What Follows?.One key shift is the rise of new players such as China, which is rapidly expanding its role in global health through the Health Silk Road and significant biotech investments.China now accounts for 23% of the global drug pipeline, offering CAR-T cancer treatments at 50–80% lower costs than in the U.S. This creates opportunities for cheaper, innovative treatments to reach low- and middle-income countries, but also raises concerns over transparency, debt sustainability, and alignment with recipient countries’ priorities.
The authors stress that emerging donors, including China, India, and Gulf states, should be engaged constructively to establish shared principles of aid effectiveness. At the same time, domestic health financing in low- and middle-income countries must grow to reduce dependency on volatile international aid flows.
For harm reduction advocates and public health leaders, this transitional period offers both risks and opportunities to shape a more inclusive and sustainable global health system.
